Similar articles

• [Current concepts in chronic lymphocytic leukemia. Better chances for young patients].

  Hallek M, Bergmann M, Goede V, Fingerle-Rowson G, Schweighofer C, Schmitt B, Wendtner CM, Emmerich B. Hallek M, et al. MMW Fortschr Med. 2003 Jul 10;145(27-28):46-9. MMW Fortschr Med. 2003. PMID: 14587189 Review. German. No abstract available.
• Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia.

  Del Poeta G, Ilaria Del Principe M, Buccisano F, Maurillo L, Niscola P, Venditti A, Amadori S. Del Poeta G, et al. Expert Rev Anticancer Ther. 2006 Dec;6(12):1787-800. doi: 10.1586/14737140.6.12.1787. Expert Rev Anticancer Ther. 2006. PMID: 17181492 Review.
• Monoclonal antibodies in chronic lymphocytic leukemia.

  Ferrajoli A, Faderl S, Keating MJ. Ferrajoli A, et al. Expert Rev Anticancer Ther. 2006 Sep;6(9):1231-8. doi: 10.1586/14737140.6.9.1231. Expert Rev Anticancer Ther. 2006. PMID: 17020457 Review.
• When and how to treat elderly patients with chronic lymphocytic leukemia (C.L.L.)? The French Cooperative Group on C.L.L.

  Binet JL. Binet JL. Hematol Oncol. 1993;11 Suppl 1:38. Hematol Oncol. 1993. PMID: 8486339 Clinical Trial. No abstract available.
• Chronic lymphoproliferative disorders.

  Montserrat E, Binet JL, Dighiero G, Gale RP, Juliusson G, Keating M, Rai KR. Montserrat E, et al. Rev Invest Clin. 1994 Apr;Suppl:52-8. Rev Invest Clin. 1994. PMID: 7886310 Review. No abstract available.